Artificial Collaborates to Enhance COVID-19 Diagnostic Testing Solution

PALO ALTO, Calif.--(BUSINESS WIRE)--Artificial today announces a strategic technology collaboration to develop an integrated and comprehensive software automation platform for Thermo Fisher’s standardized COVID-19 Testing Platform. Under the terms of the agreement, Thermo Fisher Scientific secured early access to Artificial’s software, aLab Suite, to enhance the capabilities of their standardized COVID-19 Testing Platform. Artificial’s aLab Suite is intended to seamlessly integrate with Thermo Scientific’s Momentum workflow software and robotics hardware to enable laboratories to quickly scale COVID-19 testing to volumes needed for reducing the spread of disease and restoring economies and communities.

As part of this collaboration, Artificial will provide access to aLab Suite to enable the dynamic scheduling of protocol runs with batch optimizations to maximize the number of tests run. In addition, manual protocol steps will be coordinated with the Momentum process by using digital assistants that provide users step-by-step guidance. Thermo Fisher Scientific will also provide feedback on aLab Suite functionalities and capabilities to contribute to future product requirements and system specifications.

“aLab Suite’s ability to orchestrate and optimize both manual and automated steps in a workflow will be of substantial benefit to our COVID-19 Testing Platform. With their first-of-its-kind digital tools, our partnership with Artificial represents an exciting opportunity to meet the needs of rapidly scaling COVID-19 testing for the current pandemic,” said Hansjoerg Haas, senior director and General Manager, Laboratory Automation, Thermo Fisher Scientific.

“Artificial’s aLab Suite is a great addition to Thermo Fisher’s standardized COVID-19 Testing Platform by further enabling labs to easily and quickly scale their operations while minimizing hands-on time and staffing,” said David Fuller, CEO of Artificial, “Our partnership with Thermo Fisher represents an exciting opportunity to improve COVID-19 testing throughput and the further development of aLab Suite to address the pain points of the life sciences market.”

About Artificial

Artificial empowers every lab to realize the benefits of automation for their next breakthrough by providing a first-of-its-kind software platform that keeps the human-in-the-loop. Artificial’s aLab Suite orchestrates everything that happens in a lab, including the manual tasks that still make up much of today’s lab work, to generate robust reliability and reproducibility. By bringing robotics, automation, data, and people together on a single easy-to-use platform, labs are empowered to go from scientific intent to reliable results faster and more efficiently.

For more information, please visit www.artificial.com.